NCT04222114 - Comparing the Efficacy and Safety of Intra-peritoneal Infusion of Catumaxomab and Treatment of Investigator Choice in Patients With Advanced Gastric Carcinoma With Peritoneal Metastasis | Biotech Hunter

Enrollment

282

Participants

Timeline

Start Date

October 6, 2020

Primary Completion Date

March 31, 2023

Study Completion Date

August 31, 2023

Conditions

Stomach Neoplasms

Interventions

DRUG

Catumaxomab

The starting dose of catumaxomab for intra-peritoneal infusion will be 10μg, gradually increased to 20μg, 50μg and 150μg, respectively. From the second cycle, catumaxomab will be changed to 20μg,50μg,150μg on days 1,4 and 8.

DRUG

The treatment of investigator choice

the localized supportive treatment which has been approved or recommended by local gastric cancer guidance to treat the peritoneal metastasis.

Trial Locations (13)

800

RECRUITING

Kaohsiung Medical University Chung-Ho Memorial Hospital, Kaohsiung City

100142

RECRUITING

Beijing Cancer Hospital, Beijing

RECRUITING

Peking University First Hospital, Beijing

130000

RECRUITING

The First Bethune Hospital of Jilin University., Jilin

450008

RECRUITING

Henan Cancer Hospital, Zhengzhou

510080

RECRUITING

The First Affiliated Hospital,Sun Yat-sen University, Guangzhou

Unknown

RECRUITING

Ajou University Hospital, Suwon

RECRUITING

Gangnam Severance Hospital, Yonsei University Health System, Seoul

RECRUITING

Samsung Medical Center, Seoul

RECRUITING

The Catholic University of Korea, Seoul St. Mary's Hospital, Seoul

RECRUITING

China Medical University Hospital, Taichung

RECRUITING

Chi Mei Hospital, Liouying, Tainan City

RECRUITING

National Cheng Kung University Hospital, Tainan City